Cardio-renal medicine · KIMS Secunderabad
Cardiorenal Syndrome — When the Heart and Kidneys Fail Each Other
The heart and kidneys are intimately connected — each depends on the other for normal function, and failure of either organ profoundly affects the other. Cardiorenal syndrome (CRS) describes the bidirectional interaction between cardiac and renal dysfunction — a clinical state where acute or chronic disease of one organ causes dysfunction of the other. The 2010 ADQI (Acute Dialysis Quality Initiative) classification defined five types of CRS, each representing a different direction and temporal relationship of the organ interaction. Understanding which type of CRS is present is essential for directing the correct treatment — because what helps one type may harm another.
The cardiorenal relationship creates one of the most challenging clinical management problems in medicine: the standard treatment for heart failure (aggressive diuresis with furosemide) worsens kidney perfusion and may precipitate AKI; the standard response to worsening kidney function (restricting fluid and reducing diuretics) may worsen cardiac fluid overload. Navigating this conflict requires simultaneous specialist expertise in both cardiology and nephrology — the model of care at KIMS.
The five types of cardiorenal syndrome
Type 1 — Acute cardiorenal (acute cardiac → acute kidney)
Timing: Hours to days. Scenario: Acute decompensated heart failure (ADHF), cardiogenic shock, or acute MI causing sudden reduction in cardiac output and renal perfusion — AKI develops within hours. Management: IV loop diuretics (IV furosemide) to reduce preload and improve cardiac output · inotropes if cardiogenic shock · renal support (CRRT) if diuresis insufficient · treat the cardiac cause urgently.
Type 2 — Chronic cardiorenal (chronic cardiac → progressive CKD)
Timing: Months to years. Scenario: Chronic heart failure with reduced ejection fraction causing chronically reduced cardiac output, venous congestion (high central venous pressure — transmitted to the renal veins, reducing the pressure gradient driving glomerular filtration), and neurohormonal activation (RAAS and sympathetic overactivation). CKD develops progressively. Management: optimise cardiac failure management (ACE inhibitors/ARBs, beta-blockers, diuretics, SGLT2 inhibitors) · protect residual kidney function with nephroprotective agents.
Type 3 — Acute renocardiac (acute kidney → acute cardiac)
Timing: Hours to days. Scenario: Sudden severe AKI causing fluid overload (pulmonary oedema), hyperkalaemia (causing arrhythmias), metabolic acidosis (depressing cardiac contractility), and uraemic cardiomyopathy — acute cardiac dysfunction driven by the consequences of AKI. Management: dialysis (CRRT or IHD) to remove fluid and restore electrolytes · treat the cause of AKI.
Type 4 — Chronic renocardiac (CKD → cardiac disease)
Timing: Months to years. Scenario: CKD causing chronic hypertension (driving left ventricular hypertrophy and heart failure), anaemia (cardiac volume overload), mineral-bone disorder (vascular calcification and valvular disease), uraemic toxin accumulation (endothelial dysfunction and atherosclerosis). Cardiovascular disease is the leading cause of death in CKD patients. Management: kidney-protective therapy (SGLT2 inhibitors, RAAS blockade) · erythropoietin for anaemia · phosphate control · aggressive cardiovascular risk management.
Type 5 — Secondary cardiorenal (systemic disease → both organs)
Timing: Variable. Scenario: A systemic condition damages both organs simultaneously — sepsis (the most common), diabetes, amyloidosis, SLE, sarcoidosis, vasculitis. Management: directed at the underlying systemic disease.
The worsening renal function dilemma in acute heart failure
The most common clinical challenge in CRS is acute decompensated heart failure treated with diuretics — where creatinine rises (worsening renal function — WRF) as fluid is removed. The critical clinical question is whether the WRF is haemodynamically significant (genuine under-perfusion from over-diuresis — requires reducing diuretic dose and fluid resuscitation) or haemodynamically insignificant (a transient rise in creatinine from reduced renal venous pressure as fluid is removed — tolerable if clinical decongestion is improving).
Studies show that the haemodynamically insignificant WRF — where creatinine rises modestly during decongestion but cardiac output and renal venous pressure are improving — does not predict worse long-term kidney outcomes and should not prompt reduction of diuresis. Prematurely stopping diuresis because of a rising creatinine in a patient who is still congested allows fluid overload to worsen venous congestion — which itself impairs kidney function. The CARRESS-HF trial showed that ultrafiltration was not superior to pharmacological diuresis for CRS Type 1.
The SGLT2 inhibitor — the game changer for CRS
Dapagliflozin (DAPA-HF and DAPA-CKD trials) and empagliflozin (EMPEROR-Reduced and EMPA-KIDNEY trials) reduce hospitalisation for heart failure, slow CKD progression, and reduce cardiovascular mortality in patients with both conditions — addressing both sides of the cardiorenal interaction simultaneously. SGLT2 inhibitors are now standard of care for patients with both heart failure and CKD at KIMS, in both diabetic and non-diabetic patients.
Book a Joint Cardiology-Nephrology Assessment at KIMS for Cardiorenal Syndrome
Frequently Asked Questions — Cardiorenal Syndrome
Heart failure impairs kidney function through four main mechanisms: reduced cardiac output (forward failure — less blood pumped to the kidneys, reducing glomerular perfusion pressure); elevated central venous pressure (backward failure — the congested venous system transmits high pressure to the renal veins, reducing the pressure gradient that drives glomerular filtration); neurohormonal activation (low cardiac output activates RAAS and sympathetic nervous system — angiotensin II vasoconstricts the kidneys, sodium is retained, and the kidneys begin their own failure cycle); and reduced renal prostaglandin production (the combination of low perfusion and ACE inhibitor/diuretic therapy reduces prostaglandin-mediated vasodilation in the kidneys, sensitising them to haemodynamic insults).
CKD damages the heart through multiple mechanisms: hypertension (from sodium retention and RAAS activation — causing left ventricular hypertrophy and eventually heart failure); anaemia from reduced erythropoietin (causing volume overload cardiomyopathy — the heart increases output to maintain oxygen delivery to tissues despite reduced haemoglobin); uraemic toxins (accumulating uraemic solutes impair myocardial contractility, cause endothelial dysfunction, and accelerate atherosclerosis); calcium-phosphate dysregulation (hyperphosphataemia drives vascular calcification — stiffening the aorta and coronary arteries and calcifying heart valves); and the direct inflammatory effects of CKD on the myocardium and vasculature.
Yes — and this is one of the most important advances in CRS management. SGLT2 inhibitors (dapagliflozin, empagliflozin) improve outcomes in both heart failure with reduced ejection fraction and CKD — across a wide range of eGFR values (down to eGFR 20 for empagliflozin per the EMPA-KIDNEY trial). They reduce hospitalisation for heart failure, slow CKD progression, and reduce cardiovascular mortality simultaneously. At KIMS, eligible patients with both heart failure and CKD are offered SGLT2 inhibitor therapy as part of the standard cardiorenal management protocol, in collaboration with the treating cardiologist.
Dialysis is required in CRS when: fluid overload causes refractory pulmonary oedema that does not respond to IV diuretics (ultrafiltration via dialysis removes fluid directly), hyperkalaemia rises above 6.5 mEq/L with ECG changes (from AKI in the context of heart failure), metabolic acidosis is severe (pH below 7.1), or severe AKI has developed with uraemic complications. CRRT is preferred over intermittent HD in haemodynamically unstable patients with CRS — because the slow, continuous fluid removal of CRRT is better tolerated by a failing heart than the rapid fluid shifts of intermittent HD. At KIMS, CRRT is available 24/7 for CRS patients in the cardiac ICU.
KIMS Secunderabad — Dr. V. S. Reddy (Senior Consultant Nephrologist), joint nephrology-cardiology rounds for CRS patients, SGLT2 inhibitor and RAAS blockade protocol, CRRT for fluid overload and electrolyte management, EPO and iron for cardiorenal anaemia, phosphate management, transplant programme for advanced CKD-related cardiorenal disease. NABH and NABL accredited. Call 040-4488-5000.